Physician profile
Brian Wong
NPI 1124474960
$1,615.52
in general payments reported to CMS, 2019-2025
19 companies · $236 in 2025
The $236 reported for 2025 was more than what 78% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $142 · 2021: $441 · 2022: $221 · 2023: $224 · 2024: $236 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $696.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $263.85 | 2021-2024 | Qelbree |
| Pfizer INC. | $202.00 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $192.68 | 2020-2024 | Jornay Pm |
| Abbott Laboratories | $187.73 | 2022 | |
| Merck Sharp & Dohme LLC | $167.01 | 2020-2025 | Gardasil 9, M-M-R II, Vaxneuvance |
| Corium, LLC | $141.26 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $109.02 | 2020-2021 | |
| Kaleo, INC. | $72.80 | 2021 | |
| Sanofi Pasteur INC. | $44.11 | 2023 | |
| Collegium Pharmaceutical, INC. | $35.77 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $31.14 | 2023-2025 | Bexsero |
| Adlon Therapeutics L.P. | $30.86 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $27.85 | 2025 | Spravato |
| Kyowa Kirin, INC. | $22.69 | 2025 | |
| Xeris Pharmaceuticals, INC. | $22.53 | 2025 | Recorlev |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $17.91 | 2025 | Doc Band |
| Nestle Healthcare Nutrition INC. | $16.94 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.11 | 2025 | Xifaxan |
| Ultragenyx Pharmaceutical INC. | $13.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.